## **Core Concept**
Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that binds to human immunoglobulin E (IgE). It is used in the treatment of severe persistent allergic asthma. The route of administration of omalizumab is crucial for its therapeutic effect.

## **Why the Correct Answer is Right**
Omalizumab is administered via **subcutaneous injection**. This route allows for the slow absorption of the medication into the bloodstream, which is suitable for a monoclonal antibody like omalizumab. Subcutaneous administration helps in maintaining therapeutic levels of the drug in the body, which is essential for its efficacy in reducing IgE levels and subsequently decreasing asthma symptoms.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Intravenous (IV) administration is not the standard route for omalizumab. While IV administration can provide immediate high levels of a drug, it is not necessary for omalizumab, which has a slower onset of action and is effective with less frequent dosing.
- **Option B:** Intramuscular (IM) injections are sometimes used for vaccines and certain medications, but they are not the preferred route for omalizumab. IM injections may cause more local reactions compared to subcutaneous injections.
- **Option C:** Oral administration is not suitable for omalizumab because it is a monoclonal antibody. Oral administration would lead to digestion of the antibody in the gastrointestinal tract, rendering it ineffective.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that omalizumab is specifically used for patients with severe allergic asthma who have a high level of IgE. It is not used for acute asthma attacks but rather as an add-on therapy for long-term control. Omalizumab's unique mechanism of action makes it a valuable option for patients who are not adequately controlled on inhaled corticosteroids.

## **Correct Answer:** C. Subcutaneous.